Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | LDHA | P00338 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6659770 | 1.00 | PTGS1 (0.53) | PTGS1ALDH1A1KMT2AMEN1LDHA | |
| SCHEMBL23417656 | 0.95 | ALOX15 (0.49) | PTGS1ALDH1A1KMT2AMEN1LCK | |
| SCHEMBL8410630 | 0.92 | LDHA (0.57) | ALDH1A1KMT2AMEN1LDHAACACB | |
| SCHEMBL10425937 | 0.90 | LDHA (0.56) | PTGS1ALDH1A1KMT2AMEN1LDHA | |
| SCHEMBL9819533 | 0.90 | LDHA (0.56) | PTGS1ALDH1A1KMT2AMEN1LDHA | |
| SCHEMBL9405347 | 0.90 | LDHA (0.56) | PTGS1ALDH1A1KMT2AMEN1LDHA | |
| SCHEMBL21510392 | 0.85 | TACR1 (0.50) | PTGS1ALDH1A1KMT2AMEN1TACR1 | |
| SCHEMBL18489065 | 0.84 | TAS1R3 (0.52) | ALDH1A1KMT2AMEN1LDHAACACB | |
| SCHEMBL13481269 | 0.84 | ALOX15 (0.46) | PTGS1LCK | |
| SCHEMBL1067908 | 0.84 | ALOX15 (0.46) | PTGS1KMT2ALCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227640-B2 | Palladium catalysts | INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY (SG) | 2012-07-24 | — | — | US | disclosed |
| US-8227640-B2 | Palladium catalysts | INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY (SG) | 2012-07-24 | — | — | US | disclosed |
| US-20100113832-A1 | PALLADIUM CATALYSTS | AGENCY FOR SCIENCE ,TECHNOLOGY AND RESEARCH (SG) | 2010-05-06 | — | — | US | disclosed |
| US-20100113832-A1 | PALLADIUM CATALYSTS | AGENCY FOR SCIENCE ,TECHNOLOGY AND RESEARCH (SG) | 2010-05-06 | — | — | US | disclosed |
| WO-2008118097-A1 | PALLADIUM CATALYSTS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2008-10-02 | — | — | WO | disclosed |
| EP-1030854-B1 | CATALYSTS FOR ASYMMETRIC SYNTHESIS CONTAINING RIGID CHIRAL LIGANDS | PENN STATE RES FOUND (US) | 2004-08-18 | — | — | EP | disclosed |
| US-6380416-B2 | CHIRAL BIDENTATE PHOSPHINE LIGANDS WITH CYCLIC RINGS TO RESTRICT CONFORMATIONAL FLEXIBILITY OF THE LIGANDS TO ENHANCE EFFICIENCY; STEREOSELECTIVE HYDROGENATION OF KETONES TO ALCOHOLS, AND A-ACETOAMIDOCINNAMIC ACID TO ACYLAMINO ACIDS | THE PENN STATE RESEARCH FOUNDATION | 2002-04-30 | — | — | US | disclosed |
| US-20010047113-A1 | Chiral bidentate phosphine ligands with cyclic rings to restrict conformational flexibility of the ligands to enhance efficiency; stereoselective hydrogenation of ketones to alcohols, and a-acetoamidocinnamic acid to acylamino acids | THE PENN STATE RESEARCH FOUNDATION | 2001-11-29 | — | — | US | disclosed |
| US-6278024-B1 | AS CATALYSTS FOR ASSYMETRIC SYNTHESIS | THE PENN STATE RESEARCH FOUNDATION | 2001-08-21 | — | — | US | disclosed |
| US-6207868-B1 | BASED ON CHIRAL BIDENTATE PHOSPHINE LIGANDS WITH CYCLIC RING STRUCTURES TO RESTRICT CONFORMATIONAL FLEXIBILITY, ASYMMETRIC SYNTHESIS OF ALCOHOLS BY ENANTIOSELECTIVE HYDROGENATION OF KETONES CATALYZED BY THE CHIRAL LIGANDS | THE PENN STATE RESEARCH FOUNDATION | 2001-03-27 | — | — | US | disclosed |
| CN-1281460-A | Catalysts for asymmetric synthesis containing rigid chiral ligands | PENN STATE RES FOUND (US) | 2001-01-24 | — | — | CN | disclosed |
| EP-0498507-A1 | Process for the preparation of enantiomers of alpha-amino acid derivatives by asymmetric hydrogenation | DSM N.V. (NL) | 1992-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047113-A1 | Chiral bidentate phosphine ligands with cyclic rings to restrict conformational flexibility of the ligands to enhance efficiency; stereoselective hydrogenation of ketones to alcohols, and a-acetoamidocinnamic acid to acylamino acids | ADH1A, AASDHPPT, AADAT | PTGS1 2620/4885ALDH1A1 139/4885KMT2A 391/4885 |
| US-20100113832-A1 | PALLADIUM CATALYSTS | PDCD1LG2, CD274, PDCD6IP | PTGS1 1698/4885ALDH1A1 958/4885KMT2A 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.